New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer ...

Company Announcement Net sales of DARZALEX ® in the first quarter of 2025 totaled USD 3,237 million Genmab receives royalties on worldwide net ...

During a live event, Kathleen A. Dorritie, MD, discussed updated outcomes from the GRIFFIN and PERSEUS clinical trials of quadruplet therapy in multiple myeloma.

Nasdaq-listed American Depository Receipts (ADRs) of Genmab A/S (GMAB) rose over 1% on Thursday morning after Johnson & Johnson (JNJ)announced that sales of the oncology drug Darzalex rose over 20% in ...

Genmab (GMAB) reported worldwide net trade sales of Darzalex – daratumumab -, including sales of the subcutaneous product sold as Darzalex ...

HAVING DISCUSSED IMPORTANT lymphoma and chronic lymphocytic leukemia abstracts from the 66th American Society of Hematology ...

Results from a phase 3 clinical trial, published in the New England Journal of Medicine and presented at this week's American Society of Hematology meeting, demonstrated that daratumumab ...

The addition of subcutaneous daratumumab to triplet therapy improved outcomes in transplant-ineligible or -deferred multiple myeloma. The regimen reduced risk for disease progression or death by 43%.

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...